Francisco González-Saiz

Prof. Dr. Francisco González-Saiz

Universidad de Cádiz

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Journal of Psychiatric and Mental Health Nursing
Verified
Journal Article
Closed access
PDF file
JPJose I. Pérez‐Revuelta
Jose I. Pérez‐Revuelta
RTRocío Torrecilla‐Olavarrieta
Rocío Torrecilla‐Olavarrieta
EGEdgar García‐Spínola
Edgar García‐Spínola
ÁLÁngela López‐Martín
Ángela López‐Martín
RGRafael Guerrero‐Vida
Rafael Guerrero‐Vida
JVJose Mª. Villagrán‐Moreno
Jose Mª. Villagrán‐Moreno

15 February 2023 in Patient Education and Counseling
Verified
Journal Article
Open access
JPJose I. Pérez-Revuelta
Jose I. Pérez-Revuelta
FGFrancisco González-Saiz
Francisco González-Saiz
JPJuan M. Pascual-Paño
Juan M. Pascual-Paño
JJJose M. Mongil-San Juan
Jose M. Mongil-San Juan
CRCarmen Rodríguez-Gómez
Carmen Rodríguez-Gómez
JMJose Ma Villagrán Moreno
Jose Ma Villagrán Moreno
The treatment of schizophrenia requires a prolonged, multidimensional intervention that includes antipsychotic drugs. Treatment adherence is essential to effectively control the disorder. Shared decision-making (SDM) is a strategy, supported by numerous practical and ethical arguments, that seeks to involve patients in the therapeutic process to improve treatment adherence and satisfaction. The use of this model in mental health has been limited for many intrinsic and extrinsic reasons. The results of clinical trials conducted to date have largely been disappointing, potential due to study design-related limitations. To evaluate the efficacy, in terms of treatment adherence and improvement in clinical variables, such as severity of symptoms, days of hospitalization or insight, of a carefully timed SDM model initiated immediately prior to hospital discharge in patients with schizophrenia. Single-blind, randomized clinical trial in an acute psychiatric care unit within the Andalusian Health Department to compare SDM (experimental group) to treatment as usual (TAU; control group) in a sample of patients hospitalized for an acute episode of schizophrenia or schizoaffective disorder. The study was performed between January 2014 and June 2017. The experimental group participated in SDM sessions prior to discharge with regular booster sessions over the one-year follow-up. The health care team responsible for SDM was predisposed to concordance (LatCon II scale) and received specific training in SDM. A hierarchical multiple linear regression analysis was performed to evaluate the factors independently associated with adherence, controlling for sociodemographic, clinical, and admission-related variables. Variables were assessed at admission, discharge and at 3, 6 and 12 months after discharge during the one year follow up. BARS, DAI, WAI-S, COMRADE and PANSS were used to evaluate adherence, attitude to treatment, therapeutic alliance, satisfaction and confidence with decision and clinical status, respectively. A total of 227 schizophrenic patients hospitalized with acute decompensation were evaluated; of these, 102 met all inclusion criteria and were included in the study. Most patients (95%) had prior experience with antipsychotics and most (82%) had experienced related side effects. Despite randomization, psychopathologic severity was greater in the experimental group, with a mean (SD) PANSS score of 104.08 (80) vs. 93.45 (20.30) (p < 0.05). The final regression model to explain adherence was significant (adjusted R2 = 0.384; F [df= 6] = 4.386; p < 0.001), with a direct, significant and independent association with SDM mediated by the number of booster sessions. Shared decision making with booster sessions appears to increase treatment adherence in patients with severe mental disorders. Ethical, practical, and clinical reasons support the use of strategies designed promote the use of long-term, shared decision-making in psychiatric patients, especially in schizophrenia spectrum disorder.

14 October 2019 in Journal of Dual Diagnosis
Verified
Journal Article
Closed access
Esperanza VergaraEsperanza Vergara
Esperanza Vergara
FGFrancisco González-Saiz
Francisco González-Saiz
Objective: The use of psychoactive substances has been one of the most important global public health problems over the last few decades. Among the problems associated with substance use, dual diagnosis is one of the most relevant. This study aims to investigate the predictive validity of the GHQ-28 (General Health Questionnaire-28; “probable psychiatric cases”) in relation to poor treatment outcome measured by (a) “early treatment dropout” and (b) “nonclinically relevant improvement at discharge.” Methods: A longitudinal prospective design was used. A sample of 219 substance use disorder patients, who received treatment in a therapeutic community, was selected. Patients were assessed using the GHQ-28 and the outcome variables were registered. A hierarchical logistic regression model was performed to identify factors independently associated with the outcome measure (“early treatment dropout” and “nonclinically relevant improvement at discharge”). Results: Of the total sample, 79 subjects (36%) were considered “early treatment dropouts” and 56.6% (102) presented a “nonclinically relevant improvement at discharge.” The two hierarchical logistic regression results show that being classified as a “probable psychiatric case” was significantly and directly associated with “early treatment dropout” and “nonclinically relevant improvement at discharge,” as a poor in-treatment outcome indicator. Conclusions: The results of this study support the notion that the probable psychiatric cases identified by the GHQ-28 scale have a greater probability of “early treatment dropout” and have a greater probability of “nonclinically relevant improvement in discharge” of the therapeutic community. These data indicate that GHQ-28 is a suitable clinical instrument for predicting dropout and treatment effect in residential substance use disorder treatment.


6 October 2023 in Schizophrenia Research
Verified
Journal Article
Closed access
LMLeticia I. Muñoz-Manchado
Leticia I. Muñoz-Manchado
JPJose I. Perez-Revuelta
Jose I. Perez-Revuelta
ABArka Banerjee
Arka Banerjee
LGLiliana Galindo-Guarin
Liliana Galindo-Guarin
MBMiquel Bernardo
Miquel Bernardo
EFEmilio Fernández-Egea
Emilio Fernández-Egea

6 July 2017 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
PAP. Araos
P. Araos
Esperanza VergaraEsperanza Vergara
Esperanza Vergara
FGFrancisco González-Saiz
Francisco González-Saiz
MPMaría Pedraz
María Pedraz
NGNuria García-Marchena
Nuria García-Marchena
FFFernando Rodriguez De Fonseca
Fernando Rodriguez De Fonseca
Cocaine continues to be a worldwide public health concern in Europe. To improve prognosis and intervention, it is necessary to understand the characteristics of the patients who depend on the services where they receive care. The objective is to analyze the differences among patients who use cocaine and between ambulatory and residential resources to better adapt treatment. This is a descriptive, observational study of two populations of cocaine users in treatment: the ambulatory therapeutic community (ATC) and the therapeutic community (TC). The PRISM diagnostic interview was used for both groups. An analysis of both populations indicates a high prevalence of cocaine, heroin, cannabis, sedative, psychostimulant, and hallucinogen use disorders in the TC population compared to the ATC. In alcohol use disorder, differences between both mental health services were not observed. The degree of severity of cocaine use disorders (CUD) is greater in the TC population. The prevalence of psychiatric comorbidity is not statistically significant between the two populations, except for primary psychotic disorders, which are more prevalent in the TC population. This difference in the prevalence of psychotic disorders may be related to the high prevalence of cannabis use disorders in TC patients. Differences in the prevalence of substance use disorders, severity of CUD, and psychiatric comorbidity may limit the efficiency of mental health services involved in substance use disorder therapeutics. These results suggest the need for careful and extensive phenotyping of patients to improve intervention and prognosis in a clinical resource-dependent manner.